Edgar Filing: IDM PHARMA, INC. - Form SC 13G

IDM PHARMA, INC. Form SC 13G August 26, 2005

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G

Under the Securities Exchange Act of 1934*

IDM PHARMA, INC. (Name of Issuer)

Common stock, par value \$0.01 per share (Title of Class of Securities)

449394105 (CUSIP Number)

August 16, 2005 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

| | Rule 13d-1 (b) X Rule 13d-1 (c) _ Rule 13d-1 (d) |
|--|--|
| respec | remainder of this cover page shall be filled out for a reporting person's initial filing on this form with ct to the subject class of securities, and for any subsequent amendment containing information which could the disclosures provided in a prior cover page. |
| Sectio | information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of on 18 of the Securities Exchange Act of 1934 ("Act") or otherwise to the liabilities of that section of the Act hall be subject to all other provisions of the Act (however, see the Notes). |
| | (Continued on following pages) |
| CUSIP No. 449394105 | |
| 1. NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) | |
| Sanofi-Aventis | |
| Not a | pplicable |
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) _ (b) _ |
| 3. | SEC USE ONLY |

| 4. CITI | ZENSHIP OR PLACE OF ORGANIZATION |
|-----------------------------|---|
| The Repub | lic of France |
| Number o | 5. SOLE VOTING POWER |
| Shares Beneficial Owned by | lly 6. SHARED VOTING POWER 0 shares |
| Each Reporting Person | 7. SOLE DISPOSITIVE POWER |
| With: | 8. SHARED DISPOSITIVE POWER 1,986,740 shares |
| 9. AGG | REGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
| 1,986,740 | |
| 10. CH | ECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* |
| | LI |
| 11. PEI | RCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
| 15.1% | |
| | PE OF REPORTING PERSON* |
| CO | |
| | |
| Item 1(a). | Name of Issuer: |
| | IDM PHARMA, INC. |
| Item 1(b). | Address of Issuer's Principal Executive Offices: |
| 5820 Nanc | y Ridge Drive, San Diego CA 92121 |
| Item 2(a). | Name of Person Filing: |
| | Sanofi-Aventis |
| Item 2(b). | Address of Principal Business Office, or if none, Residence: |
| | 174 avenue de France |

Edgar Filing: IDM PHARMA, INC. - Form SC 13G

75013 Paris France Item 2(c) Citizenship: The Republic of France Item 2(d). Title of Class of Securities: Common Stock of IDM PHARMA, INC., par value \$0.01 per share Item 2(e). CUSIP Number: 449394105 Item 3. Item 3 is not applicable. Item 4(a). Amount Beneficially Owned: 1,986,740 shares Item 4(b). Percent of Class: 15.1 % Item 4(c). Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 1,986,740 shares (ii) Shared power to vote or to direct the vote: None (iii) Sole power to dispose or to direct the disposition of: None (iv) Shared power to dispose or to direct the disposition of: 1,986,740 shares Item 5. Ownership of Five Percent or Less of a Class: Item 5 is not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person: Item 6 is not applicable.

Edgar Filing: IDM PHARMA, INC. - Form SC 13G

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

Item 7 is not applicable.

Item 8. Identification and Classification of Members of a Group:

Item 8 is not applicable.

Item 9. Notice of Dissolution of Group:

Item 9 is not applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SANOFI-AVENTIS

Date: August 26, 2005 By: /s/ Patricia Kodyra

Patricia KODYRA
Associate Vice President
Financial and Securities Law